Abstract
OBJECTIVE: It is unclear whether the ability to respond to vaccines is restored by antiretroviral therapy. We evaluated the influenza-specific immune responses elicited by a virosomal vaccine in HIV-infected children on long-term successful highly active antiretroviral therapy (HAART). METHODS: This was an observational, prospective, open-label study enrolling 24 HIV-infected, HAART-treated (85 months' mean exposure), vaccine-naive children (median age = 11.9 years) and 14 age- and gender-matched healthy controls. Mean CD4 T-cell counts (>900 cells/μL) and percentages (>37%) were comparable. The HIV RNA level was 40% of patients) and seroprotection (Ab titer ≥1:40 in >70% of patients) was achieved at 1 month in both groups; however, fewer HIV-infected children fulfilled these criteria. The A/H3N2- and A/H1N1-specific Ab geometric mean titers were lower in HIV-infected children compared with healthy controls at 1 and 6 months; interestingly, a boost in vaccine-specific IgG3 T helper 1 type Ab was seen in healthy controls alone. Finally, vaccine specific-IFNγ- and IL-2-producing T lymphocytes were reduced at both time points in HIV-infected children compared with healthy controls. CONCLUSIONS: One injection of virosomal-adjuvanted influenza vaccine stimulates good immune responses, although the humoral and cellular immune responses are reduced in HIV-infected children compared to healthy children. This indicates that immunologic function impairments may persist upon HIV infection even if HIV-positive viremia is suppressed and immune recovery seems to be achieved.
| Original language | English |
|---|---|
| Pages (from-to) | 289-296 |
| Number of pages | 8 |
| Journal | Journal of Acquired Immune Deficiency Syndromes |
| Volume | 48 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jul 1 2008 |
Fingerprint
Keywords
- HIV infection
- Immunology
- Influenza
- Pediatrics
- Vaccine
ASJC Scopus subject areas
- Infectious Diseases
- Pharmacology (medical)
- Virology
- Immunology
Cite this
Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy. / Viganò, Alessandra; Zuccotti, Gian Vincenzo; Pacei, Michela; Erba, Paola; Castelletti, Eleonora; Giacomet, Vania; Amendola, Antonella; Pariani, Elena; Tanzi, Elisabetta; Clerici, Mario.
In: Journal of Acquired Immune Deficiency Syndromes, Vol. 48, No. 3, 01.07.2008, p. 289-296.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Humoral and cellular response to influenza vaccine in HIV-infected children with full viroimmunologic response to antiretroviral therapy
AU - Viganò, Alessandra
AU - Zuccotti, Gian Vincenzo
AU - Pacei, Michela
AU - Erba, Paola
AU - Castelletti, Eleonora
AU - Giacomet, Vania
AU - Amendola, Antonella
AU - Pariani, Elena
AU - Tanzi, Elisabetta
AU - Clerici, Mario
PY - 2008/7/1
Y1 - 2008/7/1
N2 - OBJECTIVE: It is unclear whether the ability to respond to vaccines is restored by antiretroviral therapy. We evaluated the influenza-specific immune responses elicited by a virosomal vaccine in HIV-infected children on long-term successful highly active antiretroviral therapy (HAART). METHODS: This was an observational, prospective, open-label study enrolling 24 HIV-infected, HAART-treated (85 months' mean exposure), vaccine-naive children (median age = 11.9 years) and 14 age- and gender-matched healthy controls. Mean CD4 T-cell counts (>900 cells/μL) and percentages (>37%) were comparable. The HIV RNA level was 40% of patients) and seroprotection (Ab titer ≥1:40 in >70% of patients) was achieved at 1 month in both groups; however, fewer HIV-infected children fulfilled these criteria. The A/H3N2- and A/H1N1-specific Ab geometric mean titers were lower in HIV-infected children compared with healthy controls at 1 and 6 months; interestingly, a boost in vaccine-specific IgG3 T helper 1 type Ab was seen in healthy controls alone. Finally, vaccine specific-IFNγ- and IL-2-producing T lymphocytes were reduced at both time points in HIV-infected children compared with healthy controls. CONCLUSIONS: One injection of virosomal-adjuvanted influenza vaccine stimulates good immune responses, although the humoral and cellular immune responses are reduced in HIV-infected children compared to healthy children. This indicates that immunologic function impairments may persist upon HIV infection even if HIV-positive viremia is suppressed and immune recovery seems to be achieved.
AB - OBJECTIVE: It is unclear whether the ability to respond to vaccines is restored by antiretroviral therapy. We evaluated the influenza-specific immune responses elicited by a virosomal vaccine in HIV-infected children on long-term successful highly active antiretroviral therapy (HAART). METHODS: This was an observational, prospective, open-label study enrolling 24 HIV-infected, HAART-treated (85 months' mean exposure), vaccine-naive children (median age = 11.9 years) and 14 age- and gender-matched healthy controls. Mean CD4 T-cell counts (>900 cells/μL) and percentages (>37%) were comparable. The HIV RNA level was 40% of patients) and seroprotection (Ab titer ≥1:40 in >70% of patients) was achieved at 1 month in both groups; however, fewer HIV-infected children fulfilled these criteria. The A/H3N2- and A/H1N1-specific Ab geometric mean titers were lower in HIV-infected children compared with healthy controls at 1 and 6 months; interestingly, a boost in vaccine-specific IgG3 T helper 1 type Ab was seen in healthy controls alone. Finally, vaccine specific-IFNγ- and IL-2-producing T lymphocytes were reduced at both time points in HIV-infected children compared with healthy controls. CONCLUSIONS: One injection of virosomal-adjuvanted influenza vaccine stimulates good immune responses, although the humoral and cellular immune responses are reduced in HIV-infected children compared to healthy children. This indicates that immunologic function impairments may persist upon HIV infection even if HIV-positive viremia is suppressed and immune recovery seems to be achieved.
KW - HIV infection
KW - Immunology
KW - Influenza
KW - Pediatrics
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=47049113479&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=47049113479&partnerID=8YFLogxK
U2 - 10.1097/QAI.0b013e3181632cda
DO - 10.1097/QAI.0b013e3181632cda
M3 - Article
C2 - 18545155
AN - SCOPUS:47049113479
VL - 48
SP - 289
EP - 296
JO - Journal of Acquired Immune Deficiency Syndromes
JF - Journal of Acquired Immune Deficiency Syndromes
SN - 1525-4135
IS - 3
ER -